LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Certara Inc

Închisă

SectorSănătate

8.86

Rezumat

Modificarea prețului

24h

Curent

Minim

8.85

Maxim

9.15

Indicatori cheie

By Trading Economics

Venit

3.5M

1.5M

Vânzări

46K

105M

P/E

Medie Sector

124.857

76.798

EPS

0.14

Marjă de profit

1.458

Angajați

1,487

EBITDA

-6.5M

23M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+50.12% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-487M

1.4B

Deschiderea anterioară

8.86

Închiderea anterioară

8.86

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Certara Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 dec. 2025, 23:54 UTC

Acțiuni populare

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dec. 2025, 23:51 UTC

Câștiguri

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dec. 2025, 23:39 UTC

Principalele dinamici ale pieței

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dec. 2025, 22:57 UTC

Achiziții, Fuziuni, Preluări

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dec. 2025, 21:40 UTC

Câștiguri

Nike Sales Tick Up, But China Weakness Persists

18 dec. 2025, 23:56 UTC

Principalele dinamici ale pieței

WiseTech Rises After Board Clears Executive Chair of Allegations

18 dec. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dec. 2025, 23:37 UTC

Market Talk
Câștiguri

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dec. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dec. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dec. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dec. 2025, 23:00 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dec. 2025, 22:59 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dec. 2025, 22:58 UTC

Achiziții, Fuziuni, Preluări

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dec. 2025, 22:57 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dec. 2025, 22:56 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dec. 2025, 22:55 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:59 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 dec. 2025, 21:35 UTC

Câștiguri

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dec. 2025, 21:31 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Greater China Rev Down 17% >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q EPS 53c >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Apparel Rev $3.91B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Equipment Rev $550M >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q N Amer Rev $5.63B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Footwear Rev $7.66B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

Comparație

Modificare preț

Certara Inc Așteptări

Obiectiv de preț

By TipRanks

50.12% sus

Prognoză pe 12 luni

Medie 13 USD  50.12%

Maxim 16 USD

Minim 9 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCertara Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

6

Cumpărare

5

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

11.27 / 12.79Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat